Over the past few years the world has come to recognize Abbott as a company dedicated to helping people live fuller and healthier lives. In this podcast series we'll talk with the healthcare leaders, the executives, and the engineers who are working everyday to develop new technologies to help people live their best lives.
All content for AbbottTalks is the property of DeviceTalks Podcast Network and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Over the past few years the world has come to recognize Abbott as a company dedicated to helping people live fuller and healthier lives. In this podcast series we'll talk with the healthcare leaders, the executives, and the engineers who are working everyday to develop new technologies to help people live their best lives.
S2 E2 - Abbott electrophysiology leaders highlight current portfolio, give glimpse of potential PFA device
AbbottTalks
44 minutes 18 seconds
1 year ago
S2 E2 - Abbott electrophysiology leaders highlight current portfolio, give glimpse of potential PFA device
In the latest episode of AbbottTalks, Abbott Cardiovascular's leaders, Christopher Piorkowski, MD, DVP and Chief Medical Officer of Electrophysiology, and Dan Kaiser, Divisional VP Product Development, Electrophysiology, delve into the vast landscape of electrophysiology and the comprehensive approach Abbott is taking towards atrial fibrillation (AFib) treatment. The conversation highlights a potentially innovative pulsed field ablation (PFA) technology and Abbott's broader AFib portfolio, showcasing a commitment to revolutionizing cardiac arrhythmia management. While the Volt™ Pulsed Field Ablation System could represent a significant leap forward with its unique capabilities for creating precise and tissue-selective lesions, Piorkowski and Kaiser emphasize the diversity and depth of solutions Abbott is developing. This includes advancements in diagnostic tools, patient monitoring, and a range of therapeutic approaches designed to offer customized and effective treatment pathways for individuals with AFib. By focusing on a holistic view of patient care, they discuss how Abbott aims to improve clinical outcomes through technological innovation and enhance patients' quality of life by making treatments more accessible, reducing procedure times, and addressing the broad spectrum of needs within the electrophysiology community. With ongoing clinical trials and research, Abbott is positioned at the forefront of addressing the unmet needs in AFib management, underlining the company's commitment to continuous innovation and patient-centered care.
Thank you to Cretex Medical for sponsoring this episode of AbbottTalks. For more information on how Cretex Medical works with medical device companies, visit www.cretexmedical.com.
Thank you for listening to the AbbottTalks Podcast. Click here to subscribe on your favorite podcast player: https://abbotttalks.castos.com/subscribe
AbbottTalks
Over the past few years the world has come to recognize Abbott as a company dedicated to helping people live fuller and healthier lives. In this podcast series we'll talk with the healthcare leaders, the executives, and the engineers who are working everyday to develop new technologies to help people live their best lives.
